Barclays’s GlucoTrack GCTK Stock Holding History

Barclays’s Portfolio GCTK Stock Details GCTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-42	Closed	-$402	–	5506
2026 Q2	$402	Buy	+42	New	+$790	﹤0.01%	5038
2025 Q3	–	Sell	-25	Closed	-$4.51K	–	5573
2025 Q2	$4.51K	Buy	+25	New	+$6.59K	﹤0.01%	4985

Other funds holding GCTK

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

Barclays's GCTK Position: Q3 2026 in Review

Barclays sold out of GlucoTrack (GCTK) in Q3 2026, closing a stake of 42 shares — an estimated $402 sold.

Barclays first reported a position in GCTK in Q2 2025 and held it in 2 quarters. The position peaked at $4.51K in Q2 2025. 4 funds tracked by Wall St. Rank hold GCTK as of Q3 2026.

Barclays reported no remaining GlucoTrack position as of Q3 2026 after selling out during the quarter.
Barclays sold 42 GlucoTrack shares in Q3 2026, an estimated $402.
Barclays first reported a position in GlucoTrack in Q2 2025 and held it in 2 quarters.
Barclays's GlucoTrack position peaked at $4.51K in Q2 2025.
4 funds tracked by Wall St. Rank held GlucoTrack as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.